1. United Therapeutics Corp. TYVASO (treprostinil) [Prescribing Information]. Research Triangle Park, NC: United Therapeutics Corp, 2017.
Google Scholar2. Benza, RL, Miller, DP, Gomberg-Maitland, M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164–172.
Google Scholar | Crossref | Medline | ISI3. Humbert, M, Morrell, NW, Archer, SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S–24S.
Google Scholar | Crossref | Medline | ISI4. McLaughlin, VV, Benza, RL, Rubin, LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915–1922.
Google Scholar | Crossref | Medline | ISI5. Thenappan, T, Ormiston, ML, Ryan, JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 2018; 360: j5492.
Google Scholar | Crossref | Medline6. Mubarak, KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010; 104: 9–21.
Google Scholar | Crossref | Medline | ISI7. Whittle, BJ, Silverstein, AM, Mottola, DM, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol 2012; 84: 68–75.
Google Scholar | Crossref | Medline | ISI8. Voswinckel, R, Enke, B, Reichenberger, F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48: 1672–1681.
Google Scholar | Crossref | Medline | ISI9. Galiè, N, Barberà, JA, Frost, AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844.
Google Scholar | Crossref | Medline | ISI10. Pulido, T, Adzerikho, I, Channick, RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818.
Google Scholar | Crossref | Medline | ISI11. Sitbon, O, Channick, R, Chin, KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533.
Google Scholar | Crossref | Medline | ISI12. White, RJ, Jerjes-Sanchez, C, Bohns Meyer, GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med 2020; 201: 707–717.
Google Scholar | Crossref | Medline13. Shapiro, S, Mandras, S, Shen, E, et al. Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 mcg (9 Breaths) 4 times daily. In: CHEST annual meeting, New Orleans, LA, 19–23 October 2019, Poster M373.
Google Scholar14. Bartolome, S, Bourge, RC, Ford, HJ, et al. The effect of inhaled treprostinil in the randomized, double-blind, placebo-controlled, phase-III BEAT study. In: PVRI annual world congress, Lima, Peru, 30 January–2 February 2020.
Google Scholar15. Ford, H, Anderson, W, Bice, T, et al. Inhaled treprostinil for patients at risk for acute respiratory distress syndrome. Chest 2019; 156: Supplement: A992–A993.
Google Scholar | Crossref16. Nathan, SD. Inhaled treprostinil in interstitial lung disease associated pulmonary hypertension: the INCREASE study. In: American Thoracic Society International Conference, Virtual, 24 June 2020.
Google Scholar17. Parikh, KS, Rajagopal, S, Fortin, T, et al. Safety and tolerability of high-dose inhaled treprostinil in pulmonary hypertension. J Cardiovasc Pharmacol 2016; 67: 322–325.
Google Scholar | Crossref | Medline18. Waxman, A, Restrepo-Jaramillo, R, Thenappan, T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021; 384: 325–334.
Google Scholar | Crossref | Medline19. Ramani, G, Cassady, S, Shen, E, et al. Novel dose–response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations. Pulm Circ 2020; 10: 204589402092395.
Google Scholar | SAGE Journals | ISI20. Benza, RL, Seeger, W, McLaughlin, VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant 2011; 30: 1327–1333.
Google Scholar | Crossref | Medline | ISI21. Preston, IR, Farber, HW. Impact of parenteral treprostinil dosing in pulmonary arterial hypertension (Abstract 156). J Heart Lung Transplant 2013; 32: S64–S65.
Google Scholar | Crossref22. Benza, RL, Gomberg-Maitland, M, Naeije, R, et al. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011; 30: 982–989.
Google Scholar | Crossref | Medline | ISI23. Tonelli, AR, Sahay, S, Gordon, KW, et al . Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies. Pulm Circ 2020; 10: 1–10.
Google Scholar24. Shapiro, S, Traiger, G, Hill, W. Safety and feasibility of doses greater than 54 mcg QID of inhaled treprostinil in pulmonary arterial hypertension. In: American Thoracic Society 2012 international conference, San Francisco, CA, New York: ATS, 18–23 May 2012, pp.A4804–A4804.
Google Scholar